Clostridium Difficile News and Research

RSS

Clostridium difficile is a type of bacterium found in human and animal waste. Clostridium difficile is a common cause of diarrhea that occurs in hospitals. It can also cause diarrhea or other intestinal disorders in patients treated with antibiotics.

Hope for treatment of childhood infections may come straight from the gut: Therapeutic poop

Call it therapeutic poop, if you will, but the best hope yet for an effective treatment of childhood infections with the drug-resistant bacterium C. difficile may come straight from the gut, according to recent research.

30 Jul 2013

FDA approves Rebiotix's IND application to begin RBX2660 Phase 2 study for recurrent CDI

Rebiotix Inc. announced today that the U.S. Food and Drug Administration has approved the company's Investigational New Drug application to begin the Phase 2 clinical study of RBX2660 for the treatment of recurrent Clostridium difficile infection.

30 Jul 2013

C. difficile bacteriophage provides new weapon to battle against superbugs

IFR microbiologists are reinvigorating a way of battling C. difficile infections that they hope will help overcome the growing problem of antibiotic resistant superbugs in hospitals.

19 Jul 2013

Celgene to discontinue treatment with REVLIMID in phase III ORIGIN trial

Celgene Corporation today announced that after consultation with the U.S. Food and Drug Administration Celgene will discontinue treatment with REVLIMID (lenalidomide) in the open-label, phase III ORIGIN trial, which enrolled 450 patients in over 100 sites in 26 countries.

18 Jul 2013

Sequella licenses Pfizer's exclusive worldwide rights to develop, commercialize sutezolid

Sequella, a clinical-stage pharmaceutical company commercializing novel antibiotics to treat life-threatening infectious diseases, today announced that it has licensed Pfizer Inc's exclusive worldwide rights to develop and commercialize sutezolid, a Phase 2 oxazolidinone antibiotic currently in development for the treatment of tuberculosis.

17 Jul 2013

Phase III study: REVLIMID meets primary endpoint in patients newly diagnosed with multiple myeloma

Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation, today announced that its phase III study (MM-020/IFM 07-01) of REVLIMID (lenalidomide) in combination with dexamethasone in patients newly diagnosed with multiple myeloma met its primary endpoint of progression-free survival.

11 Jul 2013

IDSA and ASM collaborate to guide the best use of lab tests for diagnosis of infectious diseases

A new guide developed by the Infectious Diseases Society of America (IDSA) and the American Society for Microbiology (ASM) will help physicians appropriately and accurately use laboratory tests for the diagnosis of infectious diseases. Laboratory test results drive approximately two-thirds of physicians' medical decisions.

11 Jul 2013

Infection control program and active surveillance can reduce incidence of impatient C. diff infections

A comprehensive infection control program combined with an active surveillance process significantly reduced the incidence of Clostridium difficile (C. diff) infections in a long-term acute care hospital, according to a study published in the Journal for Healthcare Quality, the peer reviewed publication of the National Association for Healthcare Quality (NAHQ).

10 Jul 2013

Data on side effects of fidaxomicin not analysed appropriately

The antibiotic fidaxomicin (trade name: Dificlir) has been approved in Germany since December 2011 for the treatment of adults who have diarrhoea caused by Clostridium difficile.

3 Jul 2013

Mayo Clinic opens new C. difficile Clinic at Rochester campus

Clostridium difficile (C. difficile) has reached an epidemic state and is the most common infectious cause of diarrhea in hospitals. Health care providers are seeing increased severity and recurrence rates of the infection. In response, Mayo Clinic has opened a C. difficile Clinic at the Rochester campus.

25 Jun 2013

Rebiotix receives FDA Fast Track designation for RBX2660 to treat patients with CDI

Rebiotix Inc. announced today that the U.S. Food and Drug Administration has granted Fast Track designation for the investigation of RBX2660 (microbiota suspension), intended for the treatment of recurrent Clostridium difficile infection.

25 Jun 2013

Rigorous interventions result in fewer infections, deaths associated with hospital-onset C. difficile

Rhode Island Hospital has reduced the incidence of hospital-associated Clostridium difficile (C. difficile) infections by 70 percent and reduced annual associated mortality in patients with hospital-associated C. difficile by 64 percent through successive implementation of five rigorous interventions , as reported in the July 2013 issue of The Joint Commission Journal on Quality and Patient Safety.

21 Jun 2013

Patients who receive antibiotics while in hospital may benefit from probiotics, say researchers

Patients in hospital who are on antibiotics may benefit from taking probiotics, according to researchers at St. Michael-s Hospital.

5 Jun 2013

Scientists work together to optimize the quality, availability of fecal microbiota transplants

Monarch Labs and the BioTherapeutics, Education & Research Foundation announced today their collaboration to develop two fecal microbiota transplantation products.

4 Jun 2013

Antidepressants can increase risk of C. difficile infection in depressed patients

Adults with depression and who receive certain types of anti-depressants have an increased risk of developing Clostridium difficile, a costly and serious hospital-associated infection, according to a new University of Michigan Health System study.

8 May 2013

Cubist receives Fast Track designation from FDA for late-stage antibiotic candidate

Cubist Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has granted the Company's late-stage antibiotic candidate ceftolozane/tazobactam (CXA-201) Fast Track status in the previously granted Qualified Infectious Disease Product indications, Hospital-Acquired Bacterial Pneumonia/Ventilator-Associated Bacterial Pneumonia and Complicated Urinary Tract Infections.

8 May 2013

University of Guelph researchers develop carbohydrate-based vaccine against gut bug

A first-ever vaccine created by University of Guelph researchers for gut bacteria common in autistic children may also help control some autism symptoms.

25 Apr 2013

ViroPharma announces results of VP20621 Phase 2 study for preventing recurrent CDI

ViroPharma Incorporated, an international biopharmaceutical company committed to developing and commercializing innovative products that address unmet medical needs and rare diseases, today announced the results of a Phase 2 study of VP20621 (non-toxigenic Clostridium difficile; NTCD) a novel treatment approach for preventing recurrent C. difficile infections.

23 Apr 2013

Unnecessary use of antibiotics in elderly women in EDs increases risk of unintended consequences

Older adults represent an important and growing demographic in emergency departments across the country, with urinary tract infections being one of the leading causes for ED visits.

23 Apr 2013

Study confirms effectiveness of UV-C-emitting device in combating pathogens in hospital environment

A recent study funded by Centers for Disease Control and Prevention Epicenters Program and published in Infection Control and Hospital Epidemiology ( Deverick H. Anderson , M.D., MPH et al., 2013) supports and expands on previously published studies confirming the effectiveness of an automated UV-C-emitting device to combat the pathogens Clostridium difficile (C. diff.), vancomycin-resistant enterococci (VRE) and Acinetobacter spp. – some of the common culprits of health care-associated infections drawing increased attention for hospitals across the country.

20 Apr 2013

Clostridium Difficile News and Research

Further Reading

Hope for treatment of childhood infections may come straight from the gut: Therapeutic poop

FDA approves Rebiotix's IND application to begin RBX2660 Phase 2 study for recurrent CDI

C. difficile bacteriophage provides new weapon to battle against superbugs

Celgene to discontinue treatment with REVLIMID in phase III ORIGIN trial

Sequella licenses Pfizer's exclusive worldwide rights to develop, commercialize sutezolid

Phase III study: REVLIMID meets primary endpoint in patients newly diagnosed with multiple myeloma

IDSA and ASM collaborate to guide the best use of lab tests for diagnosis of infectious diseases

Infection control program and active surveillance can reduce incidence of impatient C. diff infections

Data on side effects of fidaxomicin not analysed appropriately

Mayo Clinic opens new C. difficile Clinic at Rochester campus

Rebiotix receives FDA Fast Track designation for RBX2660 to treat patients with CDI

Rigorous interventions result in fewer infections, deaths associated with hospital-onset C. difficile

Patients who receive antibiotics while in hospital may benefit from probiotics, say researchers

Scientists work together to optimize the quality, availability of fecal microbiota transplants

Antidepressants can increase risk of C. difficile infection in depressed patients

Cubist receives Fast Track designation from FDA for late-stage antibiotic candidate

University of Guelph researchers develop carbohydrate-based vaccine against gut bug

ViroPharma announces results of VP20621 Phase 2 study for preventing recurrent CDI

Unnecessary use of antibiotics in elderly women in EDs increases risk of unintended consequences

Study confirms effectiveness of UV-C-emitting device in combating pathogens in hospital environment

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News